TP53 mutation + Chr del(17p)
|
CLL
|
TP53 mutation + Chr del(17p)
|
CLL
|
venetoclax + rituximab Sensitive: B - Late Trials
|
venetoclax + rituximab Sensitive: B - Late Trials
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
CLL
|
TP53 mutation + Chr del(17p)
|
CLL
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
CLL
|
TP53 mutation + Chr del(17p)
|
CLL
|
orelabrutinib Sensitive: C3 – Early Trials
|
orelabrutinib Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
CLL
|
TP53 mutation + Chr del(17p)
|
CLL
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
AML
|
TP53 mutation + Chr del(17p)
|
AML
|
MGD006 Sensitive: C3 – Early Trials
|
MGD006 Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
|
CLL
|
TP53 mutation + Chr del(17p)
|
CLL
|
zanubrutinib Sensitive: C3 – Early Trials
|
zanubrutinib Sensitive: C3 – Early Trials
|